Food and Drug Administration

Endocrinologic & Metabolic Drugs Advisory Committee

January 14, 2003




The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Replagal BLA 103977 Transkaryotic Therapeis, Inc. (HTM) (PPT)

Replagal™ Gene Activated Human aGalactosidase, Introduction, FDA (HTM) (PPT)

Agalsidase Alfa for Treatment of Fabry Disease, Transkaryotic Therapies, Inc. (HTM) (PPT)